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Abstract 
Background: There is an emerging role for flow cytometry (FC) in the assessment of 
small populations of plasma cells (PC). However, FC’s utility has been questioned due 
to consistent underestimation of the percentage of PC compared to microscopy. 
Methods: A retrospective study was performed on bone marrow samples analysed by 
8-colour FC. Plasma cell populations were classified as polyclonal or monoclonal 
based on FC analysis.  FC findings were compared with microscopy of aspirates, 
histology and immunohistochemistry of trephine biopsies, and immunofixation (IFX) of 
serum and/or urine. 
Results: FC underestimated PC compared to aspirate and trephine microscopy. The 
10% diagnostic cutoff for MM on aspirate microscopy corresponded to a 3.5% cutoff on 
FC. Abnormal plasma cell morphology by aspirate microscopy and clonality by FC 
correlated in 229 of 294 cases (78%). However, in 50 cases, FC demonstrated a 
monoclonal population but microscopy reported no abnormality. In 15 cases, 
abnormalities were reported by microscopy but not by FC. Clonality assessment by 
trephine microscopy and FC agreed in 251/280 cases (90%), but all 29 discordant 
cases were monoclonal by FC and not monoclonal by microscopy. These cases had 
fewer PC and proportionally more polyclonal PC, and when IFX detected a paraprotein, 
it had the same light chain as in the PC determined by FC.  
Conclusions: FC was more sensitive in detecting monoclonal populations that were 
small or accompanied by polyclonal PC. This study supports the inclusion of FC in the 
evaluation of PC, especially in the assessment of small populations. 
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Introduction 
Polychromatic flow cytometry (FC) is used in the assessment of plasma cells (PC) to 
identify monoclonal populations. PC are identified with CD38, CD45 and CD138 in 
combination with light scatter properties (1, 2). The two most widely used markers to 
identify abnormal PC are CD19 and CD56, and the aberrant phenotype of CD19- 
and/or CD56+ detects at least 90% of cases of neoplastic PC (2). Numerous other 
markers have been used to identify aberrant PC populations. CD20 is negative on 
polyclonal PC but may be positive on monoclonal PC (1, 3). Recent reports on minimal 
residual disease (MRD) detection in multiple myeloma (MM) recommended inclusion of 
CD27, CD81 and CD117 in addition to CD19 and CD56 (1, 3, 4).  Clonality of 
phenotypically abnormal populations can be readily assessed by intracellular κ and λ 
light chain (LC) staining (2). 
 
Assessment of PC by FC is useful in the prediction of progression of monoclonal 
gammopathy of uncertain significance (MGUS) or smouldering MM (SMM) to MM (5). 
After therapy of MM, assessment of minimal residual disease (MRD) by FC is an 
independent factor for risk of progression and survival (6, 7). FC has a role in 
assessment of circulating PC in plasma cell disorders. Enumeration of clonal circulating 
PC at the time of diagnosis of MM is a predictor of overall survival (8). Recently, the 
role of FC was reported in the staging of solitary plasmacytoma of bone. The detection 
of aberrant phenotype plasma cells by FC in a staging bone marrow sample was 
strongly associated with risk of progression to MM (9, 10). Several of these applications 
of FC involve assessment of small populations of PC. 
 
Despite numerous reports on the role of FC in the assessment of PC, there has been 
scepticism surrounding its use, due to the well-known underestimation of PC by FC as 
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compared to microscopy. Various publications report that FC underestimates PC by 
25-60% compared to microscopy (2, 11-13). Plausible explanations for this 
underestimation include hemodilution of samples sent for FC because of unavailability 
of first pull bone marrow (BM) aspirates for FC analysis (14), processing artefact due to 
inherent PC fragility causing loss of gating marker expression (15) and PC micro-
aggregation to lipid-enriched spicules and hence loss during cell isolation (11). A recent 
report demonstrated that second pull aspirates were significantly more hemodilute than 
first pull aspirates, and consequently the percentage of PC in the first pull was higher 
than in the second pull (16). Regardless of the cause, concerns about under-estimation 
of PC numbers by FC may have slowed the implementation of FC in routine 
assessment of plasma cell disorders.  
 
In the last several years, flow cytometers have been introduced into clinical laboratories 
that enable assessment of 6-10 markers simultaneously. In the case of PC, it is now 
possible to combine gating markers (such as CD38, CD45, CD138) with markers that 
identify abnormal plasma cells (such as CD19 and CD56) and intracellular kappa and 
lambda LC assessment in a single tube (17, 18). We have carried out a retrospective 
assessment of the performance of FC using 8-colour analysis in the detection of 
monoclonal PC populations in BM aspirates. We have compared FC with microscopy 
of BM aspirates, and with microscopy and immunohistochemistry of the corresponding 
trephine biopsies, and we have correlated the cellular findings with paraprotein data. 
 
Materials and methods 
Samples 
A database was constructed on all BM samples investigated for PC markers in the FC 
laboratory at St Vincent’s Hospital (SVH) over a five and a half year period, since the 
introduction of 8-colour FC. PC investigation was performed in response to relevant 
Page 4 of 27
John Wiley and Sons, Inc.
Cytometry: Part B - Clinical Cytometry
This article is protected by copyright. All rights reserved.
5 
information on the request forms, or when preliminary analysis by FC with CD38 and 
CD45 detected that over 1% of leukocytes were PC. Normally the first pull of the bone 
marrow aspirate was committed to microscopy and the second pull to FC. The 
database included FC (enumeration and immunophenotype), aspirate and trephine 
microscopy, trephine immunohistochemistry, and immunology (serum and urine 
electrophoresis (EPG) and immunofixation (IFX)). The vast majority of BM 
investigations included a trephine biopsy as well as an aspirate, consistent with 
institutional policy. Data from immunology investigations performed 2 weeks before or 
after BM analysis were included, and investigations conducted outside this timeframe 
were discarded. Where data were unavailable for particular investigations, samples 
were excluded from the analysis of that parameter. When there was more than one 
sample from the same patient, only the sample with the most complete dataset from all 
investigations was retained. 42 samples with no evidence of PC and 3 samples with 
ambiguous clonality were excluded. The project was approved by the St Vincent’s 
Hospital Human Research Ethics Committee. 
 
Flow cytometry analysis 
All samples were stained with the following reagents (clone names in brackets): CD45-
Pacific Orange or V500 (HI30), CD138-APC (MI15), CD38-Pacific Blue or V450 (HB7), 
CD19-APC-Cy7 or APC-H7 (SJ25C1), CD20-PerCP (L27), CD56-PE-Cy7 
(NCAM16.2), all sourced from Becton-Dickinson, San Jose, CA (BD) except for CD45-
Pacific Orange (Invitrogen). Samples were incubated with these antibodies for 10 
minutes, then cells were permeabilized with Fix & Perm (Invitrogen), then intracellular 
κ- and λ-LCs were stained using the cocktail; κ-FITC/λ-PE (1-155-2, TB28-2). All 
samples throughout the study were stained for the same 8 markers, with the same 
monoclonal antibodies, and, except for CD19, CD38 and CD45, with the same 
fluorochromes. 
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Samples were analysed on a FACSCanto II (BD), that was calibrated using Sphero 
Rainbow Fluorescent particles 3.0-3.4 µm (BD), and control PB samples were run daily 
to ensure quality. A stopping gate of 2000 PC and stopping time of 150 seconds was 
used. Acquisition of 50,000-100,000 total events was typically performed; in some 
cases 200,000 total events were acquired. 
 
FACSDiva software was used to analyse FC plots and gate populations of interest. 
Representative dot plots are shown in Figure 1. A 3-marker strategy comprising 
CD45/CD38/CD138 was used to gate PC. Cursors were set using cell populations 
within the samples that were not stained by the relevant antibodies. The FC plots were 
assessed by one of five pathologists for the presence of a monoclonal PC population. 
All monoclonal populations in the study contained at least 20 events, therefore with a 
95% confidence interval, the minimum population detected was 30 events (3). In 
samples where the minimum 50,000 leukocyte events were collected, the limit of 
detection was 30/50,000 =  0.06%. In monoclonal populations, if CD19 or CD56 
expression was heterogeneous, samples were defined as CD19- or CD56+ if an 
arbitrarily selected minimum of 30% of PC had that phenotype. 
 
Microscopy and paraprotein detection 
The percentage of PC in BM aspirates was calculated after performing a 500 nucleated 
cell differential count with light microscopy; where a range was given, the mean was 
taken.  The presence or absence of PC with abnormal morphology in aspirates was 
recorded. For immunohistochemistry, 4 µm sections of trephine biopsies were treated 
with heat induced epitope retrieval (HIER) and stained using standard protocols on 
Ventana BenchMark Ultra (Ventana Medical Systems). Antibodies used were CD138 
(AbD Serotec clone B-A38) at 1:100, CD56 (Dako clone 123C3) at 1:25, κ (Dako 
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polyclonal) at 1:6,000 and λ (Dako polyclonal) at 1:6,000. Visualization of antibodies 
was performed with Ultraview DAB detection and Ultraview Red detection (the latter for 
lambda with double-stained slides). 
 
Serum and urine EPG were performed using Sebia Hydragel β1-β2 kit (Sebia, Issey-
les-Moulineaux, France) and Hydragel 7 HR (Sebia), respectively according to the 
manufacturer’s instructions. Urine underwent routine static concentration prior to EPG 
(Minicon, Merck Millipore, Darmstadt, Germany). Serum and urine IFX were performed 
using Hydragel 9 IF (Sebia) according to the manufacturer’s instructions.  
 
FC, aspirate microscopy and trephine biopsy reports were made by different 
pathologists in the Immunology, Haematology and Anatomical Pathology Departments, 
respectively.  The FC was normally reported without knowledge of the other results, but 
the pathologists reporting microscopy on the aspirates and the trephines normally had 
access to the final FC report.  The paraproteins were reported independently of the 
other investigations, and paraprotein data was normally available to the pathologists 
preparing the other reports. 
 
Statistical analysis 
Statistical analysis was performed using IBM SPSS Statistics 21 software. Descriptive 
statistics were generated and datasets were assessed for normality using Shapiro-Wilk 
tests. 2-sample t-tests compared means between normally distributed data, and Mann-
Whitney U tests compared medians between non-normally distributed data. Chi-square 
analyses and phi correlations assessed associations between categorical variables. 
Data were displayed on scatter and box plots. An ANOVA compared means between 
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multiple groups. Linear regression was used to assess correlation between variables. 
Statistical significance was achieved with p<0.05. 
 
Results 
Classification of clonality and monoclonal marker expression 
Samples were analysed using the standard PC panel (CD38/CD138/CD45, IC-κ/IC-λ, 
CD19/CD20/CD56) and assessed by a pathologist for the presence of a monoclonal 
PC population, which was detected in 212 cases. These cases are referred to as 
monoclonal, although many of these also contained polyclonal PC. Of the monoclonal 
samples, 132 were kappa, 78 were lambda and 2 were biclonal kappa and lambda. A 
monoclonal population was not detected in 105 cases; these cases contained only 
polyclonal PC and are referred to as polyclonal (Table 1).  
 
Monoclonality was assessed by aberrant marker expression and LC restriction of the 
aberrant population. 80% of the monoclonal cases were CD19-, 65% were CD56+, and 
52% were CD19-/CD56+, which is consistent with previous findings (19-22). CD20, 
CD38, and CD45 were also used to detect abnormal populations.  A case in which 
CD38 and CD45 were dimmer on monoclonal PC than on accompanying polyclonal PC 
is shown in Figure 1. 10% of the monoclonal samples were CD20+; although some of 
these had some features of B cells, these cases were all classified as PC on the basis 
of microscopy, and were clearly PC on the basis of CD38, CD45 and CD138 analysis 
by FC.  Of the CD20+ cases, 6 were aberrant in both CD19 and CD56, 13 were 
aberrant in one (either CD19 or CD56) and one case was CD19+/CD56-. 
 
14 (7%) of the monoclonal cases were CD19+/CD56-.  In 10 of these, 90-100% of the 
PC were kappa or lambda, and in the remaining 4, the figure was 78-82%. Further 
evidence that these populations were indeed monoclonal was provided by other 
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investigations. All 14 cases had serum paraproteins with LC matching those 
determined by FC. In the 13 cases with trephine biopsy findings, 12 had a matching LC 
by immunohistochemistry, and in one case there were no abnormal plasma cells.   
 
In the 212 cases with a monoclonal PC population, 193 had a paraprotein analysis 
within two weeks of the BM investigation, and 175 (91%) had a detectable paraprotein. 
In all cases where a paraprotein was detected, it had the same LC as in the PC in FC 
analysis, except for one case where FC reported a kappa population and IFX reported 
2 paraproteins, one kappa and one lambda. Of the 2 cases with biclonal PC by FC, 1 
had detectable kappa and lambda paraproteins, but interestingly the other case had no 
detectable paraprotein. 
 
Polychromatic flow cytometry compared to aspirate morphology 
Figure 2 shows that, in nearly all the polyclonal samples, PC were <10% leukocytes by 
both FC and microscopy of the aspirate, whilst monoclonal cases ranged from little to 
extensive BM infiltration. Our study confirms well-known observations that the 
percentage of PC is underestimated by FC compared with microscopy, with FC under-
estimating PC percentages in nearly all cases, regardless of clonality. Nevertheless, 
there was significant correlation between the modalities. The trendline indicated that 
the 10% threshold for MM by aspirate enumeration corresponded to a 3.5% threshold 
by FC. Analysis of subsets positive or negative for CD19 or CD20 or CD56 did not 
reveal a subset with a significant difference in the underestimation of PC by FC, 
although there was a trend for CD56+ PC to be under-estimated more than CD56- PC, 
that did not achieve statistical significance (p= 0.059).  
 
 
Enumeration by FC versus trephine analysis 
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Trephine microscopy did not routinely report PC percentages, but assigned the 
abundance of PC to one of 4 categories. Enumeration by FC correlated with trephine 
analysis, with increasing FC percentages mirrored by trephine descriptors of increased 
marrow infiltration (Figure 3A). As was the case with aspirate microscopy, FC under-
estimated the percentage of bone marrow PC when compared with trephine 
microscopy. For example, when the trephine reported a moderate increase in PC (10-
33% of BM leukocytes), FC reported a median of 2.85% PC. Trephine microscopy also 
reported a higher abundance of PC compared with aspirate microscopy (Figure 3B). 
There were 15 cases in which aspirate microscopy reported that PC were less than 
<10% of leukocytes whereas trephine microscopy reported >10%, including 5 cases 
where the trephine reported >33%. 
 
 
Determination of clonality by FC compared with aspirate microscopy 
Assessment of clonality by FC was significantly associated with morphological findings 
on aspirate microscopy. In 81 cases, the PC were polyclonal by FC and normal by 
microscopy; in 148 cases the PC were monoclonal by FC and abnormal by 
microscopy.  Overall the two modalities correlated in 229/294 (78%) of cases (Table 2). 
Nevertheless, 50 cases were monoclonal by FC without morphological abnormalities, 
and 15 cases were polyclonal by FC that did exhibit morphological abnormalities.  
 
The 50 cases that were monoclonal by FC without morphological abnormalities had 
smaller PC infiltrates, with larger proportions of polyclonal PC, compared to all cases 
with morphological abnormalities (Table 3). 76% of these populations were CD19-, 
57% were CD56+ and 51% were CD19-CD56+, providing supporting evidence for an 
abnormal plasma cell compartment. EPG results of serum or urine were available for 
37 of these 50 cases and a paraprotein was detected in 32 (range 2-26 (median 7) 
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g/L). In the 32 cases, there were 21 IgG paraproteins, 4 IgA, 4 IgM, 2 Bence Jones 
proteins, and one case was biclonal IgG and IgA. In all 32 paraproteins, the LCs 
matched those detected in the PC by FC. Therefore the clonal PC populations were 
likely to be the sources of the papaproteins, and the populations were sufficiently 
substantial to produce detectable paraproteins. Of these 50 cases, 19 had no PC 
abnormalities on trephine microscopy, 27 were monoclonal on the trephine and 4 had 
no trephine. In the 19 cases with no abnormality on the trephine, FC was the only 
modality (of the 2 microscopies and FC) to detect an abnormal population. 14 of these 
19 cases had a paraprotein, and IFX was not performed in 5 cases. Therefore of the 18 
cases with monoclonal PC by flow and no abnormality on aspirate and no paraprotein, 
only 5 were contained in the group of 19 cases with monoclonal PC by flow and no 
abnormality on aspirate or trephine.    
 
15 cases were polyclonal by FC but had morphological abnormalities on aspirate 
microscopy. 11 of these cases were investigated for paraproteins; 10 had a detectable 
serum paraprotein, and all were IgG, ranging from 2-12 (median 4) g/L. These IgG 
paraproteins lend support to the significance of the abnormalities on aspirate 
microscopy. Of these 10 cases with paraproteins, only 1 had fewer than 50 PC 
detected by FC.  Nevertheless, analysis of higher cell numbers may have revealed 
monoclonal populations. Surprisingly, none of these 15 cases demonstrated a 
monoclonal PC population by trephine microscopy. In 2 of these cases, the trephine 
reported a mild increase in PC that was not considered monoclonal. Therefore in these 
15 cases, aspirate microscopy was the only modality (of the 2 microscopies and FC) to 
detect a morphologically abnormal PC population.  
 
Determination of clonality by FC compared with trephine biopsy microscopy 
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There was a high association between assessment of clonality determined by FC and 
by immunohistochemical staining of trephine biopsies. The two modalities agreed in 
251/280 (90%) of cases (Table 4). Notably, all 29 discrepant cases were reported as 
monoclonal by FC but polyclonal by trephine microscopy. Dot plots from one of these 
cases are shown in Figure 1. These 29 cases had smaller PC populations compared 
with cases identified as monoclonal by trephine microscopy, and contained 
proportionally larger polyclonal PC populations (Table 5). In most of these cases, the 
monoclonal cells had an abnormal CD19 and/or CD56 phenotype, the majority (76%) 
were CD19-, 55% were CD56+, and 34% were CD19-CD56+; only one case was 
CD19+CD56-. 
 
IFX results were available for 24 of these 29 cases, and in all but 2 cases, paraproteins 
were detected. In 20 cases, IFX revealed a single serum paraprotein with the same LC 
as in the PC according to FC, and in one case there were two paraproteins, one kappa 
and the other lambda, which matched the FC result.  In one case that was kappa by 
FC, 2 paraproteins were detected by IFX, one kappa and the other lambda. 18 of the 
paraproteins were IgG, 5 were IgA and there was 1 Bence Jones protein; their serum 
concentration ranged from 2 to 18 (median 4) g/L.  
 
Of these 29 cases, 19 had no abnormality by microscopy of the aspirate. Therefore FC 
was the only modality (of the 2 microscopies and FC) that detected a monoclonal 
population in these 19 samples. In the other 10 cases, aspirate microscopy detected 
increased PC (2.5-10%), and abnormal PC features were reported in 2 of these cases. 
In the trephine reports on these 10 cases, 6 described PC that were suspicious or 
atypical or mildly increased with uncertain significance, but monoclonality was not 
demonstrated. In the remaining 4 cases, the trephine report did not describe any PC 
abnormality. Of the 29 cases, 26 came from patients who were being assessed for a 
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plasma cell disorder, mostly following detection of a paraprotein.  In one case, a full PC 
analysis by FC was performed because the initial FC screen found that >1% of BM 
leukocytes were PC by CD38 and CD45 staining.  One case was assessment of 
treated MM, and one was staging of a solitary plasmacytoma.   
 
Discussion 
This study confirmed FC’s underestimation of PC percentages compared to 
microscopy (11-13). Only 10 samples had a higher PC percentage by FC than by 
aspirate microscopy, and in these cases the overestimation was marginal. The 
trendline suggests that for the threshold for the diagnosis of MM, a FC value of 3.5% 
could be similar to the diagnostic criterion of 10% by microscopy used by the 
International Myeloma Working Group (23). However, with a 3.5% cutoff, some 
samples that were defined as MGUS by microscopy would become SMM or MM by FC, 
and vice versa. This study was not able to fully corroborate findings by Johnsen et al. 
(24) that the PC underestimation by FC was more marked in samples that were 
CD56+, although there was a trend (p = 0.059). CD56 expression could be artificially 
depressed in aspirate specimens used in FC as CD56-mediated adhesion may make 
CD56+ PC less amenable to aspiration, although this does not explain the enumeration 
discrepancy between the investigative modalities (25).  
 
Monoclonality by FC was associated with abnormal morphology by aspirate 
microscopy (26). However there were numerous discrepant samples. There were 50 
cases with normal morphology that were monoclonal by FC (Table 2). It is unlikely that 
these populations were FC artefacts for the following reasons.  Firstly, in all cases 
where paraproteins were identified, the LC of the PC by FC had a matching LC by IFX. 
Secondly, the majority of these cases had the characteristic monoclonal phenotype of 
CD19- and/or CD56+. Thirdly, the percentages of PC reported by FC in these 50 cases 
Page 13 of 27
John Wiley and Sons, Inc.
Cytometry: Part B - Clinical Cytometry
This article is protected by copyright. All rights reserved.
14 
were lower, and polyclonal PC were more abundant, compared with the cases where 
both FC and aspirate microscopy reported abnormalities. Lower percentages of PC 
and larger proportions of polyclonal PC are likely factors that complicate detection of 
neoplastic PC by morphology. By contrast, there were 15 cases that were polyclonal by 
FC with abnormal morphology, and most of these cases had matching paraproteins, 
suggesting the PC populations were monoclonal. Patchy distribution of neoplastic PC 
within the BM, or under-representation of PC in the passes sent for FC, or insufficient 
acquisition of PC could explain the failure of FC to detect these monoclonal 
populations. 
 
Clonality assessment by trephine and FC were correlated, and there were fewer 
discordant cases than when aspirate morphology was compared with FC.  This is 
unsurprising given trephine analysis included immunohistochemical LC staining to 
assess for clonality. Furthermore, more cells are assessed on the trephine than the 
aspirate, reducing sampling error where patchy infiltration can result in false negatives 
(27). Additionally, trephine microscopy highlights PC distribution patterns indicative of 
neoplastic infiltration in the absence of elevated PC percentages or when κ-/λ-LC ratios 
are unconvincing (28, 29).  
 
Despite these advantages of trephine microscopy, there were 29 monoclonal samples 
detected by FC but missed by the trephine. In almost all cases, when a paraprotein 
was detected, its LC matched that of the PC detected by FC, providing evidence that 
these were significant monoclonal populations. Furthermore, as with the populations 
not detected by aspirate microscopy, the majority of these cases were CD19- and/or 
CD56+, providing more evidence that they were neoplastic. These cases had smaller 
PC populations and larger proportions of polyclonal PC, as was the case with the 
samples missed by aspirate morphology. These findings suggest that detection of 
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small monoclonal PC populations by microscopy is difficult, especially in the presence 
of polyclonal counterparts.  
 
A strength of this study is that the same panel of markers was used to assess PC by 
FC over several years, enabling accumulation of a large number of samples. A number 
of limitations of the study should be noted. It is a retrospective study, and in each of the 
modalities, different pathologists reported on the samples during the study period. The 
pathologists were not blinded to the other results, although the FC was normally 
reported before the other modalities. FC did not assess markers such as CD27, CD81, 
and CD117 which are now included in panels to detect MRD in MM (1, 3, 4). The study 
has potential implications for detection of small numbers of PC in assessment of MRD, 
and staging of solitary plasmacytoma of bone, and in assessment of circulating PC.  
However during the study period, few BM samples were submitted for these purposes, 
and the study did not assess circulating PC. Instead most of the samples were 
submitted for assessment of possible MM. Therefore our study does not directly 
establish the efficacy of FC in MRD, plasmacytoma staging, or circulating PC.  
 
Our finding that FC is more sensitive than microscopy in detecting small monoclonal 
PC populations is consistent with two recent reports (16, 30) using 8 or 9 colour FC. In 
one of these reports, FC was shown to be more sensitive than immunohistochemistry 
for CD138 in detecting abnormal PC in MGUS and SMM (16). In the other report, FC 
was shown to be more sensitive than microscopy with or without immunohistochemistry 
in the detection of small PC populations (30). The current report, taken together with 
these recent publications, indicates the utility of FC using 8 or more colours in the 
detection of small PC populations.  
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The findings of superior sensitivity of FC in assessing small PC populations is 
consistent with the evidence that FC is useful in evaluation of PC in a variety of settings 
where very low numbers of PC may be clinically important, such as evaluation of 
MGUS (5) and MRD (6, 7), staging of solitary bone plasmacytomas (9, 10) and 
assessment of circulating PC as a prognostic factor in MM (8). In these settings, PC 
may only be present in small numbers, making their analysis virtually impossible by 
microscopy, and detection of monoclonal PC by microscopy may be further 
confounded by the presence of polyclonal PC. By contrast, FC can readily analyse very 
large numbers of cells and can detect PC populations of 0.01% or less, and 
assessment of monoclonal populations can be determined by aberrant markers as well 
as LC analysis (12, 31).  
 
This study confirmed the underestimation of PC by FC, but nevertheless showed 
correlation between microscopy and FC in terms of PC enumeration. Overall, 
assessment of clonality correlated well between FC and microscopy. However, 
numerous samples from patients with paraproteins were monoclonal by FC, but were 
not reported as abnormal by aspirate or trephine microscopy. These results justify 
inclusion of FC in the assessment of PC disorders. 
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Tables 
Table 1: Baseline characteristics of BM samples including clonality as 
determined by FC  
Characteristic Polyclonal Monoclonal 
Total No. (n) 105 212 
Median Age (IQR) 64 (19) 67 (17) 
Male/Female (n) 72/33 126/86 
IQR: Interquartile range 
 
Table 2: Clonality assessed by FC versus morphological abnormalities assessed 
by aspirate microscopy  
 
 Aspirate microscopy  
Normal Abnormal Total 
Flow 
Cytometry 
Polyclonal 81  15  96  
Monoclonal 50  148  198 
 Total 131  163  294 
There was significant agreement in clonality assessment between the two modalities, 
chi-square p=0.000. 
 
Table 3: Fewer PC and more polyclonal PC in samples that were monoclonal by 
FC and normal by aspirate 
Characteristic 
Monoclonal by FC, 






n 50 163 - 
PC (% of BM 
leukocytes) 




2.6:1 (7.9:1) 16.3:1 (102:1) 0.000 
p-values were derived by Mann-Whitney U tests. 
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Table 4: Clonality assessed by FC versus trephine microscopy and 
immunohistochemistry 
 Trephine microscopy  
Polyclonal Monoclonal Total 
Flow 
Cytometry 
Polyclonal 78 0 78 
Monoclonal 29 173 202 
 Total 107 173 280 




Table 5: Fewer PC and more polyclonal PC in samples that were monoclonal by 
FC and polyclonal by trephine 
Characteristic 








n 29 173 - 
PC (% of BM 
leukocytes) 




1.7:1 (3.4:1) 17.6:1 (101:1) 0.000 
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Gating and immunophenotyping of plasma cells.  The figure shows dot plots from a 
bone marrow aspirate containing small numbers of plasma cells (0.4% of total cells by 
FC). Plasma cells (PC) were gated on the basis of CD38 and CD45 in panel (A), and 
confirmed to be CD138+ in panel (B). Intracellular (IC) staining with kappa and lambda 
is shown in panel (C); the blue cells are B cells.  Panels (D), (E) and (F) display PC 
only. In panel (D), CD19dimCD56+ cells (PC*), 131 events, 45% of total PC, are shown 
in purple. The other plasma cells, largely CD19+CD56-, are shown in red. Only the 
CD19dimCD56+ plasma cells are shown in panel (E) and these are kappa restricted.  
Only the other plasma cells are shown in panel (F) and these are polyclonal. 
Backgating to panel (A) reveals that the monoclonal PC are dimmer for CD38 and 
CD45 than the polyclonal PC. In this case, the monoclonal population detected by FC 
was not detected by aspirate microscopy or trephine biopsy immunohistochemistry.  
 
Figure 2 
Comparison of plasma cell numbers by FC compared to aspirate microscopy. Data are 
presented as log10 of PC percentage. The red dotted line shows where the percentage 
of PC detected by both modalities is the same. The solid black line is the trendline, and 
the black dotted lines show the 10% threshold for an MM diagnosis by aspirate 
enumeration, and the equivalent threshold of 3.5% (100.55) for FC. Linear regression 
showed correlation (R2= 0.677, p=0.000) between the modalities. The microscopy 
reports on 15 monoclonal and 36 polyclonal samples did not provide a percentage of 
PC, and these samples were not included in this analysis. 
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Figure 3 
Comparison of PC numbers by trephine microscopy with flow cytometry in panel (A) 
and with aspirate microscopy in panel (B). Descriptive categories correspond to the 
following PC percentages determined by trephine biopsy microscopy: normal/minimal 
increase (0-2%), mild increase (2-10%), moderate increase (10-33%), significant 
increase (>33%). The number of cases in each trephine biopsy category is shown (n). 
The boxes show the median and interquartile range. The upper and lower horizontal 
lines outside the boxes represent the highest and lowest values that are not outliers. 
Circles represent outliers (values >1.5 times the interquartile range). The red dotted 
horizontal reference lines indicate the 10% threshold for MM diagnosis. The trephine 
microscopy reports on 26 samples did not report a percentage of PC, and these 
samples were not included in this analysis. Medians were: Panel (A) Normal/minimal 
increase- 0.4%, mild increase- 0.8%, moderate increase- 2.8%, significant increase- 
17.6%; Panel (B) Normal/minimal increase- 2.5%, mild increase- 3.7%, moderate 
increase- 13.2%, significant increase- 37.0%. 
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